Sirakoss
Medical device company based in scotland that has developed synthetic bone graft substitutes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | 16 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
SIRAKOSS is a medical technology company specializing in advanced bone grafting solutions. The company operates in the healthcare sector, primarily serving orthopedic surgeons and medical professionals who require reliable bone healing solutions for their patients. SIRAKOSS's flagship product, Osteo 3, is a proprietary nanosynthetic bone graft substitute composed of novel inorganic granules. This product is designed to provide significantly better healing outcomes, particularly in challenging cases, by catalyzing rapid and controlled bone regeneration.
The company focuses on developing strong clinical data to support the efficacy of its products, ensuring that they meet the highest standards of medical performance. SIRAKOSS's business model revolves around the development, production, and sale of its innovative bone grafting solutions. Revenue is generated through the direct sale of Osteo 3 to hospitals, clinics, and surgical centers.
SIRAKOSS operates in a niche market within the broader medical device industry, targeting healthcare providers who require advanced solutions for bone healing and regeneration. The company's commitment to research and development, coupled with its focus on clinical efficacy, positions it as a leader in the bone grafting market.
Keywords: nanosynthetic, bone graft, Osteo 3, bone healing, orthopedic, medical technology, clinical efficacy, rapid recovery, healthcare, surgeons.